Sequencing data generated for this study have been deposited with the GEO database and can be found at accession numbers GSE118284 (rhesus macaque placenta RNA-seq), GSE118289 (human placenta RNA-seq, THE1B capture-seq, H3K4me1 and H3K27ac ChIP-seq), and GSE118283 (mouse uterus and placenta RNA-seq). Other sequencing data utilized for this study can be found at accession numbers GSE87726 (human placenta RNA-seq), GSE43520 (human and mouse placenta RNA-seq), and GSE30611 (BodyMap 2.0 human tissue RNA-seq). All other relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The complex process of completing gestation and initiating parturition must be tightly controlled to prevent the dangerous consequences of preterm or postterm birth to the mother and offspring. In humans, corticotropin-releasing hormone (CRH) production by the placenta increases exponentially with gestational age, predicting the onset of parturition \[[@pbio.2006337.ref001]\]. This exponential increase in placental CRH production has been observed earlier in the pregnancy when that pregnancy was destined to end in preterm birth and later in the pregnancy for postterm birth, indicating that placental CRH may play a role in the timing and onset of labor \[[@pbio.2006337.ref001]--[@pbio.2006337.ref004]\].

The peptide hormone CRH has a well-characterized role in the hypothalamic-pituitary-adrenal axis that is highly conserved in vertebrates \[[@pbio.2006337.ref005]\]. However, its expression in the placenta is observed only in anthropoid primate species, consistent with evolutionary changes in placental gene regulation \[[@pbio.2006337.ref006]--[@pbio.2006337.ref014]\]. One major driver of evolutionary diversity in gene regulation is the class of mobile DNA sequences known as transposable elements \[[@pbio.2006337.ref015], [@pbio.2006337.ref016]\]. Recent advances in genome sequencing, high-throughput screening for active chromatin, and computational resources facilitating comparative genomic analysis have made it possible to identify lineage-specific DNA sequences with signs of regulatory activity, many of which are derived from transposable elements \[[@pbio.2006337.ref017]--[@pbio.2006337.ref021]\].

In a recent study, species-specific enhancers active in early placental development were found to be highly enriched for long terminal repeats (LTRs), a subset of transposable elements derived from retroviruses \[[@pbio.2006337.ref022]\]. LTR regions of retroviruses utilize available host factors to recruit transcription machinery and produce virus, and isolated LTRs have been reported to function as promoters or enhancers of the host's genes \[[@pbio.2006337.ref023]--[@pbio.2006337.ref028]\]. To understand whether similar co-option of LTRs into the host's function has occurred in placental regulation of *CRH* expression, we examined the vicinity of the *CRH* gene for elements that are conserved in anthropoid primates but not present in species without placental *CRH* expression. We identified a retroviral LTR element of the transposon-like human element 1B (THE1B) family, which invaded the anthropoid primate genome approximately 50 million years ago \[[@pbio.2006337.ref029]\]. We hypothesized that the introduction of this retroviral LTR element into the genome of anthropoid primate common ancestors initiated expression of *CRH* in placental tissue. Here, we tested this hypothesis by introducing the human *CRH* locus into transgenic mouse lines and selectively editing regions of a nearby THE1B LTR element to control the expression of human *CRH* in mouse placental tissue. We show that this LTR element interacts with distal-less homeobox 3 (DLX3), a transcription factor (TF) required for placental development \[[@pbio.2006337.ref030]\]. Transgenic mice expressing human *CRH* in their placentas exhibited significant changes in their length of gestation, suggesting that placental *CRH* expression is a potential mechanism of controlling the timing of birth that is unique to anthropoid primates.

Results {#sec002}
=======

*CRH* expression and retroviral element THE1B presence are concordant in anthropoid primate placenta {#sec003}
----------------------------------------------------------------------------------------------------

Because *CRH* is expressed in placenta of anthropoid primate species only, we hypothesized that any potential regulatory DNA sequence would be conserved only in the anthropoid primate lineage. We compared the genomes of 12 anthropoid primates, 3 prosimians, and 3 nonprimate mammals in the region of *CRH* and identified an endogenous retroviral LTR of the THE1B type that correlated with placental *CRH* expression ([Fig 1A](#pbio.2006337.g001){ref-type="fig"}). THE1B LTR elements have been shown to activate transcription under certain conditions \[[@pbio.2006337.ref031], [@pbio.2006337.ref032]\]. To determine activity of this THE1B element in anthropoid primate placenta, we utilized a PCR screening system to amplify transcripts containing both THE1B and the coding exon of *CRH* from placental tissue. Both human and rhesus macaque placentas expressed a detectable fusion transcript with an identical splice junction connecting sequence downstream of THE1B to noncoding exon 1 of *CRH* ([Fig 1B](#pbio.2006337.g001){ref-type="fig"}). This novel splice junction is conserved in the primate species included in [Fig 1A](#pbio.2006337.g001){ref-type="fig"}, suggesting a possible role for THE1B as a regulatory element of *CRH* in the placenta ([S1 Table](#pbio.2006337.s008){ref-type="supplementary-material"}). The THE1B-CRH fusion transcript was detectable by PCR screening but not detectable by RNA sequencing (RNA-seq) from term human placenta, indicating low abundance relative to total *CRH* expression ([Fig 1B](#pbio.2006337.g001){ref-type="fig"}). To better detect potential THE1B-CRH fusion transcripts, we utilized a capture sequencing approach in which we first enriched for cDNAs containing THE1B elements using a library of biotinylated complementary RNA probes that could be pulled down with streptavidin beads prior to deep sequencing. Despite obtaining greater than 1,000-fold enrichment of THE1B-containing transcripts, we remained unable to detect any chimeric reads linking THE1B and *CRH*. In contrast, we found abundant reads transcribed in the antisense direction through the THE1B element ([Fig 1B](#pbio.2006337.g001){ref-type="fig"}). Because these reads are unidirectional and within 2 kb of the *CRH* promoter region, it is likely that these reads were initiated from a bidirectional *CRH* promoter. In sum, the comparative genomics and RNA-seq data led us to hypothesize that the anthropoid-specific THE1B element serves as an enhancer, not an alternative promoter, of the *CRH* gene.

![THE1B is a candidate enhancer for placenta-specific regulation of *CRH* and other genes.\
(A) Comparative genomic alignment of 16 primates and 3 nonprimate mammals (UCSC Genome Browser, hg38, accessed June 14, 2017). LTR element THE1B (red bar) is present in anthropoid primates (red lines of phylogenetic tree) and absent in prosimians and nonprimate mammals. (B) Alignment of PCR-amplified transcript (Sequenced Transcript) and reads from human placental transcriptome precapture (RNA-seq) and postcapture (Capture-seq) for THE1B-containing transcripts. Sequenced fusion transcript found in human and rhesus macaque joins THE1B to *CRH* exon 1. This transcript is not found in pre- or postcapture RNA-seq; however, THE1B is transcribed. Raw data can be found at GEO accession number GSE118289. (C) Heat map of coregulation of THE1B-associated genes in placenta relative to other tissues. THE1B-associated genes are less coregulated, and thus more divergent in expression, between placenta and other tissues when compared to a group of randomly selected genes. Numerical values and their corresponding colors represent the odds ratio of observing the effect of relative coexpression between tissue pairs, generated by nonparametric tests separately between each pair of tissues as described by Pavlicev and colleagues \[[@pbio.2006337.ref033]\]. (D) Upper right, higher percentage of human placenta--enriched genes, compared with all genes, are associated with THE1B. (*P* = 0.015 by binomial test.) Lower left, the log2fold gene expression between human and mouse of THE1B-associated human placenta--enriched genes. Raw data can be found at GEO accessions GSE118289 and GSE43520 (human placenta), GSE43520 (mouse placenta), and GSE30611 (other human tissues). Numerical data can be found in [S1 Data](#pbio.2006337.s001){ref-type="supplementary-material"}. CRH, corticotropin-releasing hormone; Endometr. strom., endometrial stromal cells; GEO, Gene Expression Omnibus; LTR, long terminal repeat; RNA-seq, RNA sequencing; THE1B, transposon-like human element 1B; UCSC, University of California, Santa Cruz.](pbio.2006337.g001){#pbio.2006337.g001}

THE1B LTRs may form a coordinated regulatory network in anthropoid primate placenta {#sec004}
-----------------------------------------------------------------------------------

Previous studies have implicated endogenous retroviral LTR elements as promoters and enhancers that drive placenta-specific gene expression \[[@pbio.2006337.ref022], [@pbio.2006337.ref033]--[@pbio.2006337.ref038]\]. To examine the effect of THE1B LTRs on placental expression of genes, including *CRH*, we first defined a set of genes that had a THE1B element within 10 kb of the transcription start site. This set of THE1B-associated genes contained 2,311 gene--THE1B pairings, encompassing about 10% of THE1B elements in the human genome. We then compared the expression pattern of THE1B-associated genes across different tissues using a relative coexpression analysis as described by Pavlicev and colleagues \[[@pbio.2006337.ref033]\]. Briefly, the analysis was run on all expressed genes and tested whether the THE1B-associated genes were equally correlated in their expression between a focal tissue and each of 17 other tissues than expected for a random size-matched subset of THE1B-unassociated genes. Consistently lower correlations in all tests involving a tissue of interest imply that some feature of THE1B-associated genes confers the particular expression status in that particular tissue, and in fact, the relative coexpression of THE1B-associated genes in tests involving placenta was significantly lower than for a random gene set ([Fig 1C](#pbio.2006337.g001){ref-type="fig"}). An association between a THE1D element and placental expression of a single gene has been reported \[[@pbio.2006337.ref039]\]; however, Pavlicev and colleagues found no change in relative coexpression of genes associated with other THE1 family members in placenta \[[@pbio.2006337.ref033]\].

In a second analysis, we quantified gene expression from RNA-seq of human and mouse tissues to identify genes with human-specific, placenta-enriched gene expression. We then examined whether these differentially expressed genes were enriched for THE1B elements within 20 kb of their promoters relative to a control set of genes. Indeed, we found a significant association of THE1B elements with human placenta--enriched genes ([Fig 1D](#pbio.2006337.g001){ref-type="fig"}). Taken together, these data show that genomic presence of THE1B is associated with differential expression of nearby genes in anthropoid primate placenta.

Enrichment of histone H3 lysine 27 acetylation (H3K27ac) or histone H3 lysine 4 monomethylation (H3K4me1), histone modifications associated with classical enhancers, was not detected at the THE1B upstream of *CRH* in chromatin immunoprecipitation sequencing (ChIP-seq) analyses performed on human placental tissue; however, other genomic THE1B elements were associated with these modifications ([S1 Fig](#pbio.2006337.s003){ref-type="supplementary-material"}).

THE1B-CRH transgenic mice express human *CRH* in placenta {#sec005}
---------------------------------------------------------

In order to study the regulation of *CRH* in placenta, we created a novel mouse model by incorporating a bacterial artificial chromosome (BAC) with the human *CRH* gene and approximately 180 kb of flanking sequence, including the THE1B LTR, into the genome of FVB/N mice ([Fig 2A](#pbio.2006337.g002){ref-type="fig"}). Random integration of this BAC resulted in two founder animals, denoted Tg(BAC1) and Tg(BAC2), which were bred independently to C57BL/6 mice and maintained as separate lines. We then tested for the presence of human *CRH* in adult tissues and determined that expression of *CRH* in Tg(BAC1)/+ and Tg(BAC2)/+ animals is remarkably specific to the hypothalamus and placenta at embryonic day 18.5 (E18.5) ([Fig 2B](#pbio.2006337.g002){ref-type="fig"}). No human *CRH* was detected in any tissues of nontransgenic littermates.

![BAC transgenic mice exhibit placental *CRH* expression and delayed parturition, which are eliminated by THE1B deletion.\
(A) Schematic of human BAC clone RP11-366K18 (gray) with *CRH* shown to scale (red). (B) Expression of human *CRH* measured by qPCR in adult tissues and placenta. (*n* = 2--4 per group, *P* \< 0.0001 by two-way ANOVA with tissue type as source of variation. Error bars indicate the standard error of the mean.) (C) Gestation length of litters homozygous for Tg(BAC1), homozygous for Tg(BAC2), or wild-type control. BAC transgenic litters have a significantly longer gestation length than wild-type control litters. (*n* = 28 +/+, *n* = 9 Tg\[BAC1\]/Tg\[BAC1\], *P* \< 0.0001 by one-way ANOVA with post hoc Tukey's multiple comparisons test. *n* = 17 Tg\[BAC2\]/Tg\[BAC2\], *P* = 0.0006 compared to +/+ by one-way ANOVA with post hoc Tukey's multiple comparisons test. Error bars indicate standard deviation.) (D) Gestation length of litters hemizygous for Tg(BAC1) or wild-type control. Litters receiving Tg(BAC1) only from the father are born significantly later than wild-type control litters. (*n* = 20 +/+, *n* = 17 Tg\[BAC1\]/+, *P* = 0.0003 by unpaired two-tailed *t*-test. Error bars indicate the standard deviation.) (E) Schematic of 5-kb region containing *CRH* (gray) and THE1B (red). Blue arrows represent PAM sequences targeted by CRISPR/Cas9. (F) Sequenced deletions of the indicated transgenic founder animals compared to the Tg(BAC1) parent line. Red text, THE1B element. Blue text, PAM sequences indicated in (A). (G) Placental expression of human *CRH* at E18.5 measured by qPCR. (*n* = 3 Tg\[BAC1\]/+, *n* = 6 Tg\[CR1\]/+, *P* = 0.0006 by one-way ANOVA with post hoc Tukey's multiple comparisons test. *n* = 5 Tg\[CR2\]/+, *P* = 0.0035 compared to Tg\[BAC1\]/+ by one-way ANOVA with post hoc Tukey's multiple comparisons test. Error bars indicate the standard error of the mean.) (H) Hypothalamic expression of human *CRH* measured by qPCR. (*n* = 3 Tg\[BAC1\]/+, *n* = 4 Tg\[CR1\]/+, *P* = 0.0033 by one-way ANOVA with post hoc Tukey's multiple comparisons test. *n* = 4 Tg\[CR2\]/+, *P* = 0.0013 compared to Tg\[CR1\]/+ by one-way ANOVA with post hoc Tukey's multiple comparisons test. Error bars indicate the standard error of the mean.) (I) Gestation length of litters homozygous for Tg(CR1), homozygous for Tg(CR2), or wild-type control. The gestation length of THE1B-deleted transgenic litters is not significantly different from wild-type control litters. (*n* = 39 +/+, *n* = 15 Tg\[CR1\]/Tg\[CR1\], *n* = 7 Tg\[CR2\]/Tg\[CR2\], *P* = 0.0568 by one-way ANOVA. Error bars indicate standard deviation.) Numerical data for B, C, D, G, H, and I can be found in [S1 Data](#pbio.2006337.s001){ref-type="supplementary-material"}. BAC, bacterial artificial chromosome; CRISPR/Cas9, clustered regularly interspaced short palindromic repeat/CRISPR-associated 9; E18.5, embryonic day 18.5; HT, hypothalamus; ND, not detected; ns, not significant; PAM, protospacer adjacent motif; qPCR, quantitative PCR; skelM, skeletal muscle; THE1B, transposon-like human element 1B.](pbio.2006337.g002){#pbio.2006337.g002}

Placental expression of human *CRH* delays parturition in transgenic mice {#sec006}
-------------------------------------------------------------------------

As expression of *CRH* in human placenta is known to correlate with timing of parturition \[[@pbio.2006337.ref001]\], we examined the timing of birth in Tg(BAC1) and Tg(BAC2) mouse lines. When compared with strain-matched control litters, Tg(BAC1)/Tg(BAC1) litters were born an average of 14.9 hours later (one-way ANOVA with Tukey post hoc, *P* \< 0.0001; [Fig 2C](#pbio.2006337.g002){ref-type="fig"}), and Tg(BAC2)/Tg(BAC2) litters were born an average of 9.3 hours later (one-way ANOVA with Tukey post hoc, *P* = 0.0006; [Fig 2C](#pbio.2006337.g002){ref-type="fig"}), suggesting that placental expression of human *CRH* is sufficient to alter gestation length in mice. This effect of CRH appears to be independent of progesterone withdrawal, as no differences were detected in maternal serum progesterone or in uterine expression of the contractile-associated proteins oxytocin receptor (*Oxtr*), connexin-43 (*Gja1*), caveolin-1 (*Cav1*), cyclooxygenase 1 (COX-1; *Ptgs1*), or cyclooxygenase 2 (COX-2; *Ptgs2*) at E18.5 ([S2 Fig](#pbio.2006337.s004){ref-type="supplementary-material"}). A significant decrease in prostaglandin F2α was noted in uterine tissue of Tg(BAC1)/Tg(BAC1) litters at E18.5 ([S2 Fig](#pbio.2006337.s004){ref-type="supplementary-material"}).

To eliminate the possibility that this alteration of gestation length was a result of hypothalamic human *CRH* expression, we repeated these experiments with C57BL/6 (nontransgenic) mothers. Wild-type mice delivering Tg(BAC1)/+ litters completed gestation an average of 11.0 hours later than strain-matched control litters (unpaired two-tailed *t*-test, *P* = 0.0003; [Fig 2D](#pbio.2006337.g002){ref-type="fig"}), associating the delayed parturition phenotype with the genotype of the fetal-derived placenta.

Deletion of THE1B by CRISPR/Cas9 eliminates placental *CRH* expression {#sec007}
----------------------------------------------------------------------

To determine if retroviral LTR THE1B is necessary for placental *CRH* expression, we used the clustered regularly interspaced short palindromic repeat/CRISPR-associated 9 (CRISPR/Cas9) system to specifically delete THE1B from the genome of Tg(BAC1) mice. We utilized two guide RNAs targeting the 5′ end of THE1B and the 3′ end immediately flanking the 366-bp THE1B sequence such that the THE1B element would be deleted by nonhomologous end joining of the surrounding sequence ([Fig 2E](#pbio.2006337.g002){ref-type="fig"}). Microinjection of guide RNAs and *Cas9* mRNA into the cytoplasm of the zygotes generated by Tg(BAC1)/+ crosses resulted in two founder animals with deletions greater than 300 bp. Sanger sequencing of the deletions revealed that the larger deletion, termed Tg(CR1), completely lacked the THE1B element ([Fig 2F](#pbio.2006337.g002){ref-type="fig"}). The other deletion, termed Tg(CR2), contained 12 bp at the 5′ end of THE1B that were deleted in Tg(CR1). This 12-bp sequence is comprised of 2 bp of THE1B sequence and 10 bp immediately upstream of the THE1B element ([Fig 2F](#pbio.2006337.g002){ref-type="fig"}).

Next, we measured the mRNA expression of human *CRH* in placenta of Tg(CR1)/+ and Tg(CR2)/+ animals at E18.5. Complete deletion of THE1B in the Tg(CR1) line abolished placental expression of human *CRH* (one-way ANOVA with Tukey post hoc, *P* = 0.0006 compared to Tg\[BAC1\]; [Fig 2G](#pbio.2006337.g002){ref-type="fig"}). The Tg(CR2) line retains 2 bp of the 5′ end of THE1B and subsequently expressed about 20% human *CRH* relative to the Tg(BAC1) parent line (one-way ANOVA with Tukey post hoc, *P* = 0.0035; [Fig 2G](#pbio.2006337.g002){ref-type="fig"}).

We next examined the effect of THE1B deletion on the other primary site of *CRH* expression, the hypothalamus. As expected, deletion of THE1B did not abolish hypothalamic expression of human *CRH* in either transgenic line. Complete deletion of THE1B in the Tg(CR1) line appeared to increase expression of human *CRH* in the hypothalamus (one-way ANOVA with Tukey post hoc, *P* = 0.0033 compared to Tg\[BAC1\], *P* = 0.0013 compared to Tg\[CR2\]; [Fig 2H](#pbio.2006337.g002){ref-type="fig"}). We detected compensatory down-regulation of mouse *Crh* in hypothalamus, resulting in no difference in serum corticosterone relative to nontransgenic mice ([S3 Fig](#pbio.2006337.s005){ref-type="supplementary-material"}). We also examined the effect of THE1B deletion on the other protein-coding gene contained on the BAC, *TRIM55*, which is a ubiquitin E3-ligase expressed in striated muscle \[[@pbio.2006337.ref040], [@pbio.2006337.ref041]\]. *TRIM55* expression was detectable by RNA-seq in Tg(BAC1) placenta but not in Tg(CR1) placenta at E18.5, demonstrating that THE1B elements may control expression of multiple genes in a region ([S4 Fig](#pbio.2006337.s006){ref-type="supplementary-material"}).

Deletion of THE1B by CRISPR/Cas9 restores wild-type gestation length {#sec008}
--------------------------------------------------------------------

To further interrogate the role of placental CRH in delayed onset of parturition, we examined the gestation length of Tg(CR1) and Tg(CR2) animals. The gestation length of litters homozygous for either Tg(CR1) or Tg(CR2) was not significantly different from strain-matched control litters (one-way ANOVA, *P* = 0.0568; [Fig 2I](#pbio.2006337.g002){ref-type="fig"}), demonstrating that complete deletion of THE1B and subsequent lack of placental CRH rescued the extended-gestation phenotype of the Tg(BAC1) parent line. Tg(CR2)/Tg(CR2) litters had unusual variability in their gestation length, which could be due to the low level of expression of *CRH* from the residual 5′ insertion site of THE1B ([Fig 2G](#pbio.2006337.g002){ref-type="fig"}). Despite this variability, Tg(CR2)/+ litters showed no differences in birth timing relative to control litters ([S5 Fig](#pbio.2006337.s007){ref-type="supplementary-material"}).

TF DLX3 interacts with THE1B 5′ insertion site {#sec009}
----------------------------------------------

Transposable elements, especially those arising from retroviral LTRs, can activate gene expression by recruiting binding of available TFs \[[@pbio.2006337.ref018], [@pbio.2006337.ref022]\]. To determine the pool of TFs present in anthropoid primate placenta when *CRH* is known to be highly expressed, we analyzed placental transcriptomes generated by RNA-seq from two human and two rhesus macaque placentas near term. We identified a set of 90 TFs expressed at 10 transcripts per million (TPM) or greater in all samples, which we defined as moderately expressed TFs, and proceeded to examine potential binding of these TFs to the THE1B sequence with the prediction tool CisBP \[[@pbio.2006337.ref042]\]. Two families of TFs known to contribute to placental trophoblast differentiation, GATA \[[@pbio.2006337.ref043]\] and DLX \[[@pbio.2006337.ref044]\], were predicted by CisBP to interact with the 5′ end of the THE1B sequence that was retained in Tg(CR2) but deleted in Tg(CR1). When tested by gel shift assay, DLX3, but not GATA2, was able to bind the 5′ end of THE1B ([Fig 3A](#pbio.2006337.g003){ref-type="fig"}). This DLX3 binding site is located at the junction of the THE1B element and the surrounding DNA ([Fig 3B](#pbio.2006337.g003){ref-type="fig"}).

![THE1B 5′ insertion site creates novel binding site for transcription factor DLX3.\
(A) Top left, sequence of 5′ insertion site of THE1B near *CRH*, predicted DLX3 binding site shown in red. Lower left, electrophoretic mobility shift assay demonstrating binding of DLX3-DDK to positive control (JRE probe) and the 5′ insertion site of THE1B (THE1B 5′ probe). The red arrow denotes the band formed by DLX3-DDK binding to labeled DNA probe; this binding is disrupted with the addition of anti-DDK but not isotype control mouse IgG. Top right, same sequence as left, predicted GATA2 binding site shown in red. Lower right, GATA2-DDK fails to bind to the 5′ insertion site of THE1B (THE1B 5′ probe) while binding positive control (TCR probe). Blue arrow denotes the supershifted band of anti-DDK, GATA2-DDK, and TCR probe. (B) DNA binding motif of transcription factor DLX3 \[[@pbio.2006337.ref046]\]. This DLX3 binding site is formed by the insertion of THE1B (right of black bar) into the genome (left of black bar). (C) ChIP for DLX3 (black bars) and RNA polymerase II (white bar) with quantitative real-time PCR. DLX3 is significantly associated with the 5′ end of THE1B and positive control (JRE) in human term placenta. ChIP-qPCR data were normalized to the IgG control for each target and presented relative to negative control (JRE distal). (*n* = 3 for all, *P* \< 0.0001 for THE1B and *P* = 0.0184 for JRE by one-way ANOVA with post hoc Dunnett's multiple comparisons test relative to JRE distal. Error bars indicate the standard error of the mean.) (D) Immunohistochemical comparison of human CRH localization in junctional zone ("jz") and labyrinth ("lab") of Tg(BAC1)/+ and wild-type littermate control. Human CRH is predominantly localized to the labyrinth in Tg(BAC1) mouse placenta. Blue, nuclei with DAPI. Magenta pseudocolor, CRH (imaged on far red). Green, background fluorescence of RBCs. Scale bars, 100 μm. (E) Quantitative real-time PCR of *Dlx3* and *CRH* in Tg(BAC1)/+ mouse placentas separated by dissection into junctional zone ("jz") and labyrinth ("lab"). *Dlx3* (black circle) is predominantly expressed in labyrinth, which is consistent with previous reports \[[@pbio.2006337.ref047]\]. (*n* = 5 Tg(BAC1)/+, *P* = 0.0003 by paired two-tailed *t*-test. Box and whiskers indicate that all data points are displayed.) *CRH* (red triangle) is undetectable in junctional zone. Numerical data for C and E can be found in [S1 Data](#pbio.2006337.s001){ref-type="supplementary-material"}. ChIP, chromatin immunoprecipitation; CRH, corticotropin-releasing hormone; DDK, aspartic acid--aspartic acid--lysine; DLX3, distal-less homeobox 3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IgG, immunoglobulin G; JRE, human glycoprotein hormone α-subunit junctional regulatory element; qPCR, quantitative PCR; RBC, red blood cell; TCR, T cell receptor; THE1B, transposon-like human element 1B.](pbio.2006337.g003){#pbio.2006337.g003}

We then performed ChIP with anti-DLX3 antibody in human term placental tissue and quantified by real-time PCR to determine the occupancy of this DLX3 binding site in vivo. DLX3 was significantly associated with the 5′ end of THE1B and with a previously described placental regulatory element \[[@pbio.2006337.ref045]\], when compared to a negative control region (one-way ANOVA with Dunnett's post hoc, *P* \< 0.0001 for THE1B and *P* = 0.0184 for human glycoprotein hormone α-subunit junctional regulatory element \[JRE\] relative to JRE distal; [Fig 3C](#pbio.2006337.g003){ref-type="fig"}).

DLX3 binding to THE1B may drive *CRH* expression in syncytiotrophoblasts {#sec010}
------------------------------------------------------------------------

In human placental tissue, the syncytium is the site of *CRH* expression and secretion into maternal and fetal circulations \[[@pbio.2006337.ref048], [@pbio.2006337.ref049]\]. We demonstrated localization of human CRH to the labyrinth of the Tg(BAC1)/+ mouse placenta, which contains mouse syncytiotrophoblasts ([Fig 3D](#pbio.2006337.g003){ref-type="fig"}). We also confirmed by quantitative PCR (qPCR) that expression of human *CRH* was absent in the junctional zone ([Fig 3E](#pbio.2006337.g003){ref-type="fig"}). Despite differences in placental morphology between human and mouse, DLX3 is produced in both human \[[@pbio.2006337.ref050]\] and mouse \[[@pbio.2006337.ref047]\] syncytiotrophoblasts. In Tg(BAC1)/+ placenta, 80%--99% of total *Dlx3* expression was localized to the labyrinth tissue (*n* = 5 Tg\[BAC1\]/+, *P* = 0.0003 by paired two-tailed *t*-test; [Fig 3E](#pbio.2006337.g003){ref-type="fig"}).

Discussion {#sec011}
==========

Here, we present a case of anthropoid primate--specific placental gene expression induced by retroviral LTR insertion into the genome. Our study provides evidence that an LTR element found in a separate evolutionary lineage is capable of operating as a novel placental enhancer in another species. Placental tissue is globally hypomethylated and remarkably hospitable to endogenous retroviral elements \[[@pbio.2006337.ref051], [@pbio.2006337.ref052]\]. Endogenous retroviral LTRs have been co-opted for placenta-specific expression of hormones \[[@pbio.2006337.ref035]\], endothelial factors \[[@pbio.2006337.ref037], [@pbio.2006337.ref053]\], and immune receptors \[[@pbio.2006337.ref039]\]. Several of the THE1B-associated genes in our study that are expressed at significantly higher levels in human relative to mouse placenta have been previously implicated in human placental function, including the regulation of birth timing (*CGA* \[[@pbio.2006337.ref054]\], *CRH* \[[@pbio.2006337.ref001]\]) and adverse pregnancy outcomes like preeclampsia (*ADAM12*, *PGF* \[[@pbio.2006337.ref055]\], *ZFAT* \[[@pbio.2006337.ref056]\], *TUSC3* \[[@pbio.2006337.ref057]\]) and recurrent miscarriage (*ADM* \[[@pbio.2006337.ref058]\]). These findings suggest that THE1B elements likely influence the expression of a network of genes in human placenta and that this network of THE1B-associated genes may contribute to proper placental function.

Despite several lines of evidence implicating THE1B as an enhancer for *CRH*, we did not detect classical enhancer chromatin marks (H3K27Ac, H3K4me1) on this element in human term placental samples. It is possible that the THE1B near *CRH* enhances transcription using a different mechanism than the majority of vertebrate enhancers or, alternatively, that the positive enhancer signal is being diluted by the cells within the placenta that do not express *CRH*.

Previous studies of the species specificity of placental *CRH* expression have predominantly focused on the proximal promoter sequence of *CRH* \[[@pbio.2006337.ref059], [@pbio.2006337.ref060]\]. Scatena and Adler reported no expression of a luciferase reporter construct containing the 5-kb upstream region including THE1B in rat choriocarcinoma cells; this and other experiments led them to conclude that the species specificity of placental *CRH* expression was caused by *trans*-acting factors \[[@pbio.2006337.ref059]\]. Our BAC transgenic mouse model incorporates both the human *CRH* and the mouse *Crh* promoter sequences and flanking regions; thus, differences in expression in this model are due to sequence differences rather than *trans*-acting factor availability. We observed differences in *CRH* expression when the THE1B sequence was intact (Tg\[BAC1\] and Tg\[BAC2\]), partially intact at the 5′ end (Tg\[CR2\]), and absent (Tg\[CR1\]), suggesting that the 5′ end of the THE1B LTR and its upstream insertion site are disproportionally active in the regulation of *CRH* in placenta.

The partially intact region of THE1B in Tg(CR2) mice contains an active binding site for the TF DLX3. DLX3 is present in mouse placenta and required for trophoblast differentiation; mice lacking *Dlx3* are unable to develop past embryonic day 10 due to placental failure \[[@pbio.2006337.ref030]\]. The coexpression of *Dlx3* and *CRH* in Tg(BAC1) mouse placenta further associates DLX3 availability and THE1B-dependent expression of *CRH*. Notably, the DLX3 site occurs where the THE1B element joins the surrounding sequence, suggesting a possible mechanism for activation of this particular LTR upon retroviral insertion into the anthropoid primate common ancestral genome.

Our study is the first, to our knowledge, to provide evidence that placental expression of *CRH* in a nonprimate model alters gestation length. Surprisingly, human *CRH* expression in the placentas of our transgenic mice resulted in postterm rather than preterm birth. Although uterine prostaglandin F2α was significantly lower in Tg(BAC1) animals, progesterone withdrawal and expression of contractile-associated proteins were unaffected, indicating that CRH may alter birth timing without impeding luteolysis. Previous studies have shown that CRH plays a role in myometrial quiescence, inhibiting myometrial contractility at low CRH concentration \[[@pbio.2006337.ref061]--[@pbio.2006337.ref063]\]. This inhibition of uterine contractility is consistent with the postterm birth effect seen in our mouse model. These data suggest that CRH may be a factor contributing to the extended gestational period of anthropoid primates and that increased production of CRH in pregnancies ending prematurely may be an attempt to block the progression toward preterm labor and delivery.

The extraordinary diversity found in eutherian placental gene expression is thought to result from conflict between mother and fetus in determining optimal conditions for fetal development and maternal investment \[[@pbio.2006337.ref064]--[@pbio.2006337.ref066]\]. Placental tolerance to LTRs may play a role in this ongoing evolutionary conflict by providing a mechanism for rapid changes in gene expression. Our study demonstrates that retroviral insertion of an LTR such as THE1B can alter gene expression at the level of an individual gene and potentially across the entire placental tissue. Conservation of both THE1B and placental *CRH* expression in anthropoid primate species and the correlation of maternal serum CRH concentrations with gestation length support our assertion that the THE1B-CRH regulatory system is critical for birth timing.

Materials and methods {#sec012}
=====================

Human and rhesus tissue collection, RNA-seq, and transcriptome analysis {#sec013}
-----------------------------------------------------------------------

Human (GEO accession: GSE87726) and rhesus macaque (*Macaca mulatta*; GEO accession: GSE118284) placental transcriptomes were generated as previously described \[[@pbio.2006337.ref067], [@pbio.2006337.ref068]\]. Briefly, two human placentas were collected by cesarean section at 39 weeks 1 day and 39 weeks 2 days gestational age (IRB protocol: CCHMC IRB 2013--2243). Two macaque placentas were collected by cesarean section at 128 days and 131 days gestational age (80% completed gestation). RNA was extracted from placental biopsies with the TRIzol reagent (ThermoFisher Scientific) according to the manufacturer's instructions. After passing initial quality control metrics, RNA-seq of the four samples was performed on an Illumina HiSeq machine using a paired-end approach with 50-bp reads, generating approximately 30 million paired reads per sample (human) and 15 million paired reads per sample (macaque). The reads were aligned and pseudocounted using kallisto \[[@pbio.2006337.ref069]\]. To make the two transcriptomes comparable, we used the set of genes that are orthologous between the two species and recalculated the levels of expression of single genes in each species based only on this set. The levels are expressed on a TPM scale \[[@pbio.2006337.ref070]\].

PCR screening for THE1B-CRH fusion transcript in human and rhesus {#sec014}
-----------------------------------------------------------------

Human and rhesus placental RNA was converted to cDNA using the QuantiTect Reverse Transcriptase Kit (Qiagen) according to manufacturer's instructions. PCR screening was performed with primers specific to THE1B and *CRH* exon 2 (forward: 5′-CCTCCCCTACCATGTGAAAA-3′, reverse: 5′-GGAAGAAATCCAAGGGCT-3′) as well as with internal primers downstream of THE1B and in *CRH* exon 1 (forward: 5′- TGCTGTGCATAGCTTCTCCTC-3′, reverse: 5′-TGCCTCTGCTCCTGCATAAA-3′). PCR products were examined by agarose gel electrophoresis and confirmed by Sanger sequencing.

Relative coexpression analysis of THE1B-associated genes {#sec015}
--------------------------------------------------------

The statistical test for the effect of the presence of THE1B in the vicinity of the gene on the tissue-specific expression is described in detail by Pavlicev and colleagues \[[@pbio.2006337.ref033]\]. Briefly, we compared the correlation between tissues based on the expression (expressed as the square root of the TPM value) of THE1B-associated genes to the correlation between tissues based on THE1B-absent genes. We repeated this procedure for all pair-wise tissue combinations. If the THE1B elements confer no particular status to the genes, this ratio corr~THE1B+~/corr~THE1B−~ should be close to 1 for every pair-wise tissue comparison. The significance of the effect was assessed based on the null distribution of the statistics for each pair of tissues compared, generated by randomly resampling 5,000 times the set of genes size matched to the number of THE1B-associated genes and calculating the statistics.

THE1B capture array and analysis {#sec016}
--------------------------------

Total RNA was purified from term placentas using a combination of TRIzol and Qiagen columns. RNA-seq libraries were prepared using the SureSelect Strand-Specific RNA Library Prep for Illumina Multiplexed Sequencing kit (Agilent). For capture sequencing, preamplified RNA-seq libraries were enriched for THE1B containing transcripts using a custom panel of 120 nt THE1B RNA oligos and the SureSelect^XT^ RNA Target Enrichment kit (Agilent). Libraries were sequenced as 75-bp paired-end reads on an Illumina HiSeq machine. Reads were aligned to the human genome (hg19) using Tophat2 (-I 100000---max-segment-intron 100000 -r 300) \[[@pbio.2006337.ref071]\]. Data are available at GEO accession GSE118289.

Annotation of human placenta--enriched genes {#sec017}
--------------------------------------------

We compiled a collection of RNA-seq data for different human and mouse tissues from different resources, including (1) newly generated (GEO accession: GSE118289) and public (GEO accession: GSE43520) data for human placenta, (2) data for mouse placenta (GEO accession: GSE43520), and (3) data for different human tissues (brain, heart, kidney, liver, lung, ovary, skeletal muscle, and testis) from BodyMap 2.0 (GEO accession: GSE30611). Reference genome and gene annotation files for human (GRCh38) and mouse (GRCm38) were downloaded from the ENSEMBL database. Human placenta--enriched genes were identified by a procedure comparing human placenta against other human tissues and against mouse placenta. In brief, we first quantified gene expression levels for different samples as TPM using RSEM \[[@pbio.2006337.ref072]\]. Then, we focused the analysis on the 13,068 1-to-1 orthologous genes between human and mouse according to ENSEMBL orthologue annotation. After the TPM values were normalized among different samples using the trimmed mean of M-values (TMM) method \[[@pbio.2006337.ref073]\], differential expression analyses between human placenta and other analyzed human tissues and mouse placenta were performed using Rank Product method \[[@pbio.2006337.ref074]\], with an FDR cutoff of 0.15. Finally, human placenta--enriched genes were annotated as genes that show significantly higher expression in human placenta against other human tissues and mouse placenta.

Association analysis between human placenta--enriched genes and THE1B subfamily {#sec018}
-------------------------------------------------------------------------------

We obtained repeat annotations for human THE1B subfamily from the RepeatMasker website (<http://www.repeatmasker.org/>) on May 27, 2016. To determine if the THE1B subfamily is associated with human placenta--enriched genes, we first determined the overlapping between THE1B repeat elements and promoter (defined as 20 kb upstream the longest transcript for each gene) for each protein-coding gene using the windowBed function of bedtools \[[@pbio.2006337.ref075]\]. Then, the occurrences of THE1B in all these genes and in human placenta--enriched genes were counted. Finally, Binomial Test was performed to test if the THE1B subfamily is significantly associated with human placenta--enriched genes.

Ethics statement {#sec019}
----------------

The Cincinnati Children's Hospital Medical Center Institutional Animal Care and Use Committee approved all animal experiments for this study under IACUC protocol number 2017--0051. Animal procedures were designed and executed according to the guidelines of the National Institutes of Health.

Establishment of transgenic mouse lines {#sec020}
---------------------------------------

Human BAC RP11-366K18 was obtained from the CHORI BACPAC repository. DNA was amplified and purified from bacteria using NucleoBond BAC kit (Clontech) and dissolved in polyamine buffer for microinjection. To generate lines Tg(BAC1) and Tg(BAC2), FVB/N zygotes were used for pronuclear injection of purified BAC DNA at 0.5 ng/ul and transferred into pseudopregnant CD-1 mice. The resulting pups were genotyped for presence of the human BAC with primers specific to human *CRH* (forward: 5′-TTTCTAATGTGAAAACTGCGTGAT-3′, reverse: 5′-ACACGTGGGAATTATGGGGG-3′). Transgenic lines were maintained as hemizygotes by crossing to C57BL/6 mice for 3--4 generations.

To delete the THE1B in the BAC transgenic mice, we selected 6 guide RNAs targeting the THE1B flanking region (3 per end), based on the web design tool (<http://www.genome-engineering.org>). Selected guide RNAs were cloned into pX458 vector (addgene \#48138) and validated in HEK293 cells by T7E1 assay as described by Ran and colleagues \[[@pbio.2006337.ref076]\]. Two validated guide RNAs (target sites: 5′-ATACATTTTGGATAATGATA-3′ and 5′-AGACAAATACAGATAAATTG-3′), along with *Cas9* mRNA, were introduced by cytoplasmic injection into zygotes obtained from Tg(BAC1) mice \[[@pbio.2006337.ref077]\]. Injected embryos were transferred into pseudopregnant CD-1 mice. The resulting pups were screened for deletions to the THE1B region with primers flanking THE1B (forward: 5′-CAGTTTGTGTGCCTCTGCTG-3′, reverse: 5′-CTCCCATTGGGCTATCTGGG-3′) by PCR and Sanger sequencing.

Mouse tissue collection and RNA isolation {#sec021}
-----------------------------------------

Male mice were housed with females overnight to determine time of conception. Pregnant female mice were killed on the designated day of gestation, and placentas were harvested, dissected into labyrinth and junctional zone where indicated, and flash frozen in liquid nitrogen. Tissue from the tail of corresponding embryos was used to determine placental genotype with primers specific to human *CRH*, as described earlier. Hypothalamus, kidney, heart, liver, lung, and leg quadriceps muscle tissue were harvested from adult transgenic animals and littermate controls of both sexes, and tissues were immediately frozen in liquid nitrogen. Tissues were homogenized using stainless steel beads in a TissueLyser II apparatus (Qiagen), and RNA was purified using the RNeasy Mini Kit (Qiagen). Heart and skeletal muscle RNA was purified using the RNeasy Fibrous Tissue Mini Kit (Qiagen). Labyrinth and junctional zone RNA was purified using the TRIzol reagent (ThermoFisher Scientific) according to manufacturer's instructions.

qPCR for human *CRH* expression in transgenic mice {#sec022}
--------------------------------------------------

Mouse tissue RNA was converted to cDNA using the QuantiTect Reverse Transcriptase Kit (Qiagen) according to manufacturer's instructions. Human *CRH* was quantified using the TaqMan system with TaqMan Gene Expression Master Mix (ThermoFisher Scientific) and specific probes for human *CRH* (Hs01921237_s1, ThermoFisher Scientific) and for mouse *Gapdh* as endogenous control (Mm99999915_g1, ThermoFisher Scientific). Labyrinth and junctional zone expression was quantified with specific probes for human *CRH* (Hs00174941_m1, ThermoFisher Scientific), mouse *Dlx3* (Mm00438428_m1, ThermoFisher Scientific), and eukaryotic 18S as endogenous control (catalog 4310893E, ThermoFisher Scientific). A 50-ng cDNA template was used per well, and samples were run in triplicate. qPCR reactions were run on an Applied Biosystems StepOnePlus Real-Time PCR instrument.

Localization of human CRH by immunohistochemistry/immunofluorescence {#sec023}
--------------------------------------------------------------------

Placentas of E18.5 pups were fixed in 4% paraformaldehyde in PBS overnight at 4 °C, washed in PBS, and dehydrated in 70% ethanol before embedding in paraffin. Paraffin sections were cut using a microtome. Sections were deparaffinized, incubated in citrate buffer pH 6.0 for antigen retrieval, and incubated in methanol with hydrogen peroxide for peroxidase activity removal. Following washes, slides were incubated with 5% goat serum and 4% fish skin gelatin for 60 minutes. Slides were incubated with CRH primary antibody (rabbit, Peninsula Lab T-4036, 1:1,000) overnight at 4 °C. Following washes, slides were incubated with secondary antibody (biotinylated goat anti-rabbit, Vector Lab BA-1000, 1:250) for 60 minutes. Tyramide amplification was performed with TSA cyanine 5 reagent kit (Perkin Elmer) according to manufacturer protocol.

Quantification of gestation length in transgenic mice {#sec024}
-----------------------------------------------------

Experimental animals and their respective control animals were generated by crossing hemizygous transgenic mice and subsequently crossing their homozygous offspring such that all study animals were the offspring of littermates. Male mice were housed with nulliparous female mice from approximately 1900 to 2200 hours once per week to precisely control time of conception. Pregnant females were monitored by observation from E17.5 until delivery. Pups were counted and weighed individually on the day of birth. Females were excluded from the study if there were fewer than four pups in the litter, if the female was older than 240 days of age on the date of conception, if the female was in labor for longer than 12 hours, or if the entire litter could not be delivered because of dystocia.

Binding site prediction of placental TFs {#sec025}
----------------------------------------

Human and rhesus macaque placental transcriptome data were analyzed as previously stated. TFs expressed at 10 or greater TPM were populated into the predictive program CisBP \[[@pbio.2006337.ref042]\]. Binding sites were predicted using the position-weight matrix (PWM)--LogOdds setting (threshold 8).

Electrophoretic mobility shift assay for binding at THE1B {#sec026}
---------------------------------------------------------

Immortalized extravillous trophoblast cell line HTR8/SVneo (obtained from the American Type Culture Collection, item number CRL-3271) was transfected with Lipofectamine3000 (ThermoFisher Scientific) and overexpression vector (DLX3 or GATA2 Myc-DDK vectors, Origene) for 72 hours according to manufacturer protocol. Cytoplasmic protein fraction was isolated by suspending cell pellet in cytoplasmic lysis buffer (10 mM HEPES, 10 mM KCl, 1.1 mM EDTA in dH~2~O) and adding 10% Nonidet-P40. Nuclear protein fraction was subsequently isolated by suspending nuclear pellet in nuclear lysis buffer (20 mM HEPES, 0.4 M KCl, 1 mM EDTA in dH~2~O). DNA probes were generated with IRDye700 at the 5′ end (GATA2 TCR probe: 5′-CACTTGATAACAGAAAGTGATAACTCT-3′ \[[@pbio.2006337.ref078]\], DLX3 JRE probe: 5′-GGGGGGTAATTACAGGCCC-3′ \[[@pbio.2006337.ref079]\], THE1B 5′ probe: 5′-GGATAATGATATGGTTAGA-3′). Binding reactions were performed using the Odyssey EMSA Buffer Kit (LICOR Biosciences) according to manufacturer protocol with primary antibody (monoclonal anti-FLAG M2, Sigma-Aldrich F3165) or isotype control (mouse IgG, Abcam ab37355) and run on 6% TBE gels with 0.5× TBE buffer (ThermoFisher Scientific). Gels were imaged on the Odyssey CLx Imaging System (LICOR Biosciences).

ChIP and qPCR {#sec027}
-------------

Human placental tissue was homogenized in aliquots of 100 mg tissue per mL PBS with protease inhibitor (Abcam ab65621). Homogenate was transferred to a new tube with 18-gauge needle and syringe to ensure single cell suspension. Crosslinking was performed by adding 1.5% formaldehyde to suspension and incubating at room temperature for 10 minutes. Glycine was added to a final concentration of 125 mM to stop crosslinking reaction. Cells were washed twice with PBS and resuspended in SDS Lysis Buffer (Millipore). Cell lysate was sonicated to an average of 500-bp fragments with a Covaris S220 instrument at 175 peak power for 7 minutes. Immunoprecipitation was performed with the EZ-ChIP kit (Millipore) according to manufacturer protocol. Mouse anti-RNA pol II (Millipore 05-623B) and Control Mouse IgG antibodies (Millipore 12-371B) were used as a positive and negative control according to EZ-ChIP protocol. For DLX3 ChIP, rabbit anti-DLX3 (Abcam ab66390) and rabbit IgG isotype control (Abcam ab171870) were used at 5 μg per immunoprecipitation. qPCR reactions were run on an Applied Biosystems StepOnePlus Real-Time PCR instrument with primers specific to GAPDH (forward: 5′-TACTAGCGGTTTTACGGGCG-3′, reverse: 5′- TCGAACAGGAGGAGCAGAGAGCGA-3′), JRE (forward: 5′- TGACCTAAGGGTTGAAACAAGATAAG-3′, reverse: 5′- GGAAATTCCATCCAATGATTGA-3′) \[[@pbio.2006337.ref045]\], distal region of JRE (forward: 5′- AGTTTCTTTGTGGATGAAGAGATAGACG-3′, reverse: 5′- TTTTCCGAACTTCAAAGGCCCTG-3′) \[[@pbio.2006337.ref045]\], and the 5′ end of the THE1B near CRH (forward: 5′- TTTCTAATGTGAAAACTGCGTGA-3′, reverse: 5′- ACACGTGGGAATTATGGGGG-3′).

Statistical analysis {#sec028}
--------------------

Statistical analysis was performed with GraphPad Prism (GraphPad Software) and R Statistical Programming Language. Specific statistical tests are described above.

Supporting information {#sec029}
======================

###### Numerical data and statistical analysis for Figs [1D](#pbio.2006337.g001){ref-type="fig"}, [2B, 2C, 2D, 2G, 2H, 2I](#pbio.2006337.g002){ref-type="fig"}, [3C and 3E](#pbio.2006337.g003){ref-type="fig"} and for [S2A, S2B, S2C](#pbio.2006337.s004){ref-type="supplementary-material"}, [S3A, S3B](#pbio.2006337.s005){ref-type="supplementary-material"} and [S5](#pbio.2006337.s007){ref-type="supplementary-material"} in separate sheets.

(XLSX)

###### 

Click here for additional data file.

###### Materials and methods for supporting information.

(DOCX)

###### 

Click here for additional data file.

###### THE1B near *CRH* is not associated with classical enhancer chromatin marks.

\(A\) Comparison of reads from human placental transcriptome pre-THE1B capture (RNA-seq) and post-THE1B capture (Capture-seq) to ChIP-seq reads for H3K27ac and H3K4me1 at the THE1B near *CRH*. This THE1B element lacks these chromatin marks, which are commonly associated with enhancers. (B) Comparison of reads from human placental transcriptome pre-THE1B capture (RNA-seq) and post-THE1B capture (Capture-seq) to ChIP-seq reads for H3K27ac and H3K4me1 at several THE1B elements near the *GRIK1* gene. Enrichment of these chromatin marks may indicate enhancer activity. Raw data for A and B can be found at GEO accession number GSE118289. ChIP-seq, chromatin immunoprecipitation sequencing; GEO, Gene Expression Omnibus; H3K4me1, histone H3 lysine 4 monomethylation; H3K27ac, histone H3 lysine 27 acetylation; RNA-seq, RNA sequencing; THE1B, transposon-like human element 1B.

(TIF)

###### 

Click here for additional data file.

###### Postterm birth phenotype is independent of progesterone and contractile-associated protein changes but may involve prostaglandin F2α.

\(A\) Progesterone concentration in maternal serum at E18.5. (*n* = 5--10 per group, *P* = 0.6342 by one-way ANOVA. Error bars indicate the standard error of the mean.) (B) Prostaglandin F2α concentration in uterine tissue at E18.5 is significantly lower in Tg(BAC1) litters and approaches significance in Tg(BAC2) litters. (*n* = 7--11 per group, *P* = 0.0021 by one-way ANOVA. When compared to +/+, *P* = 0.0012 for Tg\[BAC1\]/Tg\[BAC1\] and *P* = 0.0635 for Tg\[BAC2\]/Tg\[BAC2\] by post hoc Dunnett's multiple comparisons test. Error bars indicate the standard error of the mean.) (C) Expression of contractile-associated proteins in uterus of Tg(BAC1) and control animals measured by RNA-seq at E18.5. (*n* = 4 +/+, *n* = 3 Tg\[BAC1\]/Tg\[BAC1\]. All error bars indicate the standard error of the mean and were analyzed by unpaired two-tailed *t*-test. *Oxtr*, *P* = 0.6795. *Gja1*, *P* = 0.3005. *Cav1*, *P* = 0.4035. *Ptgs1*, *P* = 0.9313.) *Ptgs2* expression was uniformly very low (TPM \< 3.5 for all samples, *P* = 0.6485). Raw data can be found at GEO accession GSE118283. Numerical data for A, B, and C can be found in [S1 Data](#pbio.2006337.s001){ref-type="supplementary-material"}. E18.5, embryonic day 18.5; GEO, Gene Expression Omnibus; RNA-seq, RNA sequencing; TPM, transcripts per million.

(TIF)

###### 

Click here for additional data file.

###### Hypothalamic-pituitary-adrenal axis function in transgenic mice is comparable to control.

\(A\) Relative expression of mouse *Crh* in hypothalamus. Expression of *Crh* is down-regulated to compensate for addition of *CRH* expression in transgenic mouse hypothalamus. (*n* = 3 all groups, *P* = 0.0068 by one-way ANOVA. When compared to +/+, *P* = 0.0340 for Tg\[BAC1\]/+ and *P* = 0.0030 for Tg\[CR2\]/+ by post hoc Dunnett's multiple comparisons test. Error bars indicate the standard error of the mean.) (B) Nadir and peak corticosterone ("CORT") concentration in the serum of male (left) and female (right) transgenic mice. (*n* ≥ 3 all groups, *P* = 0.6568 for males and *P* = 0.9978 for females by two-way ANOVA, with genotype as the source of variation. Error bars indicate the standard error of the mean.) Numerical data for A and B can be found in [S1 Data](#pbio.2006337.s001){ref-type="supplementary-material"}.

(TIF)

###### 

Click here for additional data file.

###### *TRIM55* expression is altered by deletion of THE1B from the human BAC.

Gene expression from the human BAC in mouse placenta measured by paired-end RNA-seq. The only other protein-coding gene on the BAC, *TRIM55*, is located in a tail-to-tail orientation very close to *CRH*. Tg(BAC1) animals express *TRIM55* and *CRH* in placenta, whereas Tg(CR1) animals do not. Red bar, highlighted region of BAC RP11-366K18 shown to scale. Raw data can be found at GEO accession GSE118283. BAC, bacterial artificial chromosome; GEO, Gene Expression Omnibus; RNA-seq, RNA sequencing; THE1B, transposon-like human element 1B.

(TIF)

###### 

Click here for additional data file.

###### Gestation length of litters hemizygous for Tg(CR2) is not significantly different from wild-type control.

Gestation length of Tg(CR2)/+ and control litters. Although Tg(CR2) transgenic animals retain a small amount of placental *CRH* expression, litters receiving Tg(CR2) only from the father have no difference in gestation length when compared to wild-type control litters. (*n* = 14 +/+, *n* = 12 Tg\[CR2\]/+, *P* = 0.6397 by unpaired two-tailed *t*-test. Error bars indicate standard deviation.) Numerical data can be found in [S1 Data](#pbio.2006337.s001){ref-type="supplementary-material"}.

(TIF)

###### 

Click here for additional data file.

###### THE1B-CRH novel splice site is conserved in anthropoid primate species.

Red text denotes predicted splice sites for anthropoid primate species. Primate genome sequences from UCSC Genome Browser, accessed February 27, 2018. CRH, corticotropin-releasing hormone; THE1B, transposon-like human element 1B.

(DOCX)

###### 

Click here for additional data file.
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